According to Protalix BioTherapeutics 's latest financial reports and stock price the company's current number of shares outstanding is 73,036,569. At the end of 2024 the company had 73,036,569 shares outstanding. The number of outstanding shares is usually impacted by stock plits and shares buy back.
Year | Shares Outstanding | Change |
---|---|---|
2024 | 73.03 M | 1.04% |
2023 | 72.28 M | 46.03% |
2022 | 49.49 M | 8.65% |
2021 | 45.55 M | 38.62% |
2020 | 32.86 M | 121.48% |
2019 | 14.83 M |
Company | Shares Outstanding | differencediff. | Country |
---|---|---|---|
Pfizer PFE | 5,657,000,000 | 7,645.44% | ๐บ๐ธ USA |
Neurocrine Biosciences
NBIX | 99,800,000 | 36.64% | ๐บ๐ธ USA |
Amicus Therapeutics
FOLD | 302,903,009 | 314.73% | ๐บ๐ธ USA |
Teva Pharmaceutical Industries TEVA | 1,123,000,000 | 1,437.59% | ๐ฎ๐ฑ Israel |